Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. / Mylam, Karen J; El-Galaly, Tarec C; Hutchings, Martin; Brown, Peter; Himmelstrup, Bodil; Gerke, Oke; Gillstrøm, Dorte; Sillesen, Ida B; Munksgaard, Lars; Pedersen, Bjarne B; Christiansen, Ilse; Jensen, Paw; Nielsen, Anne L; Pedersen, Lars M.

In: Leukemia and Lymphoma, Vol. 55, No. 7, 07.2014, p. 1563-1569.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mylam, KJ, El-Galaly, TC, Hutchings, M, Brown, P, Himmelstrup, B, Gerke, O, Gillstrøm, D, Sillesen, IB, Munksgaard, L, Pedersen, BB, Christiansen, I, Jensen, P, Nielsen, AL & Pedersen, LM 2014, 'Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma', Leukemia and Lymphoma, vol. 55, no. 7, pp. 1563-1569. https://doi.org/10.3109/10428194.2013.850165

APA

Mylam, K. J., El-Galaly, T. C., Hutchings, M., Brown, P., Himmelstrup, B., Gerke, O., Gillstrøm, D., Sillesen, I. B., Munksgaard, L., Pedersen, B. B., Christiansen, I., Jensen, P., Nielsen, A. L., & Pedersen, L. M. (2014). Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia and Lymphoma, 55(7), 1563-1569. https://doi.org/10.3109/10428194.2013.850165

Vancouver

Mylam KJ, El-Galaly TC, Hutchings M, Brown P, Himmelstrup B, Gerke O et al. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia and Lymphoma. 2014 Jul;55(7):1563-1569. https://doi.org/10.3109/10428194.2013.850165

Author

Mylam, Karen J ; El-Galaly, Tarec C ; Hutchings, Martin ; Brown, Peter ; Himmelstrup, Bodil ; Gerke, Oke ; Gillstrøm, Dorte ; Sillesen, Ida B ; Munksgaard, Lars ; Pedersen, Bjarne B ; Christiansen, Ilse ; Jensen, Paw ; Nielsen, Anne L ; Pedersen, Lars M. / Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 7. pp. 1563-1569.

Bibtex

@article{22dd9c41d28a4e0b8502cf5e4f533622,
title = "Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma",
abstract = "The aim of this study was to evaluate the prognostic value of clinician interpretation of positron emission tomography/computed tomography (PET/CT) reports at mid-therapy, interim PET (I-PET) and after the end of first-line therapy (E-PET) in patients with diffuse large B-cell lymphoma (DLBCL). Four hundred and thirty patients were enrolled in this study comprising a total of 617 PET reports. Each report was evaluated by three expert hematologists randomly selected from a panel of nine. Reports were labeled positive or negative if all three interpreters agreed. All others were considered indeterminate. Indeterminate reports accounted for 59% of I-PET and 49% of E-PET reports. Two-year overall survival (OS) for patients with a positive, indeterminate and negative I-PET was 58%, 87% and 89% (p < 0.001), respectively. Two-year OS for patients with E-PET was 41%, 89% and 97% (p < 0.001) for positive, indeterminate and negative interpretation of PET/CT reports. Progression-free survival and OS did not differ significantly in patients with a negative and an indeterminate I-PET report. The use of well-defined reporting criteria, e.g. the Deauville five-point scale, is likely to reduce the number of scans perceived as indeterminate.",
author = "Mylam, {Karen J} and El-Galaly, {Tarec C} and Martin Hutchings and Peter Brown and Bodil Himmelstrup and Oke Gerke and Dorte Gillstr{\o}m and Sillesen, {Ida B} and Lars Munksgaard and Pedersen, {Bjarne B} and Ilse Christiansen and Paw Jensen and Nielsen, {Anne L} and Pedersen, {Lars M}",
year = "2014",
month = jul,
doi = "10.3109/10428194.2013.850165",
language = "English",
volume = "55",
pages = "1563--1569",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis",
number = "7",

}

RIS

TY - JOUR

T1 - Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma

AU - Mylam, Karen J

AU - El-Galaly, Tarec C

AU - Hutchings, Martin

AU - Brown, Peter

AU - Himmelstrup, Bodil

AU - Gerke, Oke

AU - Gillstrøm, Dorte

AU - Sillesen, Ida B

AU - Munksgaard, Lars

AU - Pedersen, Bjarne B

AU - Christiansen, Ilse

AU - Jensen, Paw

AU - Nielsen, Anne L

AU - Pedersen, Lars M

PY - 2014/7

Y1 - 2014/7

N2 - The aim of this study was to evaluate the prognostic value of clinician interpretation of positron emission tomography/computed tomography (PET/CT) reports at mid-therapy, interim PET (I-PET) and after the end of first-line therapy (E-PET) in patients with diffuse large B-cell lymphoma (DLBCL). Four hundred and thirty patients were enrolled in this study comprising a total of 617 PET reports. Each report was evaluated by three expert hematologists randomly selected from a panel of nine. Reports were labeled positive or negative if all three interpreters agreed. All others were considered indeterminate. Indeterminate reports accounted for 59% of I-PET and 49% of E-PET reports. Two-year overall survival (OS) for patients with a positive, indeterminate and negative I-PET was 58%, 87% and 89% (p < 0.001), respectively. Two-year OS for patients with E-PET was 41%, 89% and 97% (p < 0.001) for positive, indeterminate and negative interpretation of PET/CT reports. Progression-free survival and OS did not differ significantly in patients with a negative and an indeterminate I-PET report. The use of well-defined reporting criteria, e.g. the Deauville five-point scale, is likely to reduce the number of scans perceived as indeterminate.

AB - The aim of this study was to evaluate the prognostic value of clinician interpretation of positron emission tomography/computed tomography (PET/CT) reports at mid-therapy, interim PET (I-PET) and after the end of first-line therapy (E-PET) in patients with diffuse large B-cell lymphoma (DLBCL). Four hundred and thirty patients were enrolled in this study comprising a total of 617 PET reports. Each report was evaluated by three expert hematologists randomly selected from a panel of nine. Reports were labeled positive or negative if all three interpreters agreed. All others were considered indeterminate. Indeterminate reports accounted for 59% of I-PET and 49% of E-PET reports. Two-year overall survival (OS) for patients with a positive, indeterminate and negative I-PET was 58%, 87% and 89% (p < 0.001), respectively. Two-year OS for patients with E-PET was 41%, 89% and 97% (p < 0.001) for positive, indeterminate and negative interpretation of PET/CT reports. Progression-free survival and OS did not differ significantly in patients with a negative and an indeterminate I-PET report. The use of well-defined reporting criteria, e.g. the Deauville five-point scale, is likely to reduce the number of scans perceived as indeterminate.

U2 - 10.3109/10428194.2013.850165

DO - 10.3109/10428194.2013.850165

M3 - Journal article

C2 - 24144339

VL - 55

SP - 1563

EP - 1569

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -

ID: 135497347